Marvel Biosciences (TSXV:MRVL) ROCE % : 0.00% (As of Oct. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Marvel Biosciences's annualized ROCE % for the quarter that ended in Oct. 2024 was 0.00%.

Marvel Biosciences ROCE % Historical Data

The historical data trend for Marvel Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences ROCE % Chart

Marvel Biosciences Annual Data

Trend

Jul20

Jul21

Jul22

Jul23

Jul24

ROCE %

-802.52

-88.73

-200.16

Marvel Biosciences Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
ROCE %	Get a 7-Day Free Trial													-	-	-	-	-

Marvel Biosciences ROCE % Calculation

Marvel Biosciences's annualized ROCE % for the fiscal year that ended in Jul. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2024 )		(A: Jul. 2023 )		(A: Jul. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2024 )		(A: Jul. 2023 )		(A: Jul. 2024 )
	=	0	/	( ( (0.672 - 1.392)	+	(0.491 - 1.607) )	/ 2 )
	=	0	/	( (-0.72	+	-1.116)	/ 2 )
	=	0	/	-0.918
	=	0.00 %

Marvel Biosciences's ROCE % of for the quarter that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	-0.968	/	( ( (0.491 - 1.607)	+	(0.229 - 1.601) )	/ 2 )
	=	-0.968	/	( ( -1.116	+	-1.372 )	/ 2 )
	=	-0.968	/	-1.244
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

Marvel Biosciences (TSXV:MRVL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Marvel Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MBCOF:USA

Address

505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2

Website

https://www.marvelbiotechnology.com

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Executives